SOUTH SAN FRANCISCO, California, May 27, 2026
Human Longevity, Inc. (HLI) has announced the creation of Human Life Foundation Models, Inc. (HLFM), a new company dedicated to developing large-scale artificial intelligence foundation models for longevity science. Simultaneously, HLFM has entered a multi-year strategic collaboration with Insilico Medicine to build what the companies describe as the world’s first comprehensive AI foundation model specifically designed for human longevity research. By combining Human Longevity’s extensive multi-omic and clinical datasets with Insilico Medicine’s expertise in generative AI, deep learning, and drug discovery, the collaboration aims to accelerate breakthroughs in disease prediction, aging biology, preventive medicine, and longevity therapeutics. The initiative represents a major milestone in the convergence of biotechnology, artificial intelligence, and precision medicine, targeting a global longevity economy projected to reach trillions of dollars in value over the coming decade.
New AI Foundation Model Aims to Decode Human Aging
The newly formed Human Life Foundation Models (HLFM) will focus on building advanced multimodal AI systems trained on some of the most comprehensive health datasets assembled to date. Human Longevity has spent more than a decade collecting and integrating large-scale genomic, proteomic, imaging, clinical, and longitudinal health information from thousands of individuals. This extensive repository provides a unique foundation for training sophisticated AI models capable of identifying biological patterns associated with aging, disease progression, and overall health outcomes.
Through the collaboration, HLFM will leverage Human Longevity’s de-identified datasets alongside Insilico Medicine’s cutting-edge artificial intelligence infrastructure to create predictive models capable of understanding complex biological processes. The companies believe these next-generation foundation models could transform healthcare by shifting the focus from disease treatment to disease prevention, enabling earlier interventions and more personalized health strategies.
Researchers envision AI systems capable of detecting disease risks years or even decades before symptoms emerge, allowing healthcare providers to implement proactive interventions that improve quality of life and extend healthy lifespan. This approach reflects a growing industry trend toward predictive and preventive medicine powered by advanced computational technologies.
Advertisement
Combining AI and Multi-Omics Data to Accelerate Therapeutic Discovery
A central objective of the partnership is the development of AI-driven longevity therapeutics and novel approaches to age-related disease prevention. Insilico Medicine has established itself as a leader in generative AI for drug discovery, utilizing machine learning platforms to identify biological targets, design new therapeutic candidates, and accelerate pharmaceutical development.
By integrating multimodal biological data with advanced foundation models, the collaboration aims to uncover previously hidden relationships between genetics, molecular pathways, disease progression, and aging. These insights could support the discovery of new therapeutic targets and enable the development of precision interventions designed to extend healthspan and reduce age-associated disease burden.
The companies expect the platform to generate innovations across multiple areas, including early disease detection, predictive health risk modeling, personalized longevity interventions, and AI-assisted drug discovery. Such capabilities could significantly shorten research timelines while improving the probability of identifying clinically relevant therapeutic opportunities.
The initiative also highlights the growing role of artificial intelligence as a foundational technology within modern biotechnology, where computational models increasingly contribute to scientific discovery and clinical development efforts.
Privacy-Preserving Architecture Supports Global Healthcare Innovation
An important feature of the collaboration is its commitment to privacy-preserving artificial intelligence. Rather than centralizing patient-level data, the companies have adopted a decentralized architecture that keeps sensitive health information within local environments while enabling AI model development across multiple institutions and jurisdictions.
Under the framework, Insilico Medicine will not have direct access to identifiable patient data, while HLFM will coordinate secure model training within controlled environments that comply with regulatory, ethical, and data sovereignty requirements. This approach is intended to support large-scale global AI development without compromising patient privacy or data security.
The companies believe this model could serve as a blueprint for future biomedical AI initiatives, balancing scientific innovation with responsible data governance. As healthcare systems increasingly adopt artificial intelligence technologies, maintaining trust, transparency, and regulatory compliance remains essential to successful implementation.
With the launch of HLFM and its strategic partnership with Insilico Medicine, Human Longevity is taking a major step toward creating an AI-powered ecosystem capable of transforming longevity science. By combining large-scale biological datasets, multimodal artificial intelligence, predictive health analytics, and drug discovery expertise, the collaboration aims to redefine how aging is understood and managed, potentially opening a new era of preventive healthcare and longevity-focused therapeutics.
Source: Human Longevity press release
